Regional differences in the characteristics and treatment of patients participating in an international heart failure trial

Barry M. Massie, John G F Cleland, Paul W. Armstrong, Milton Packer, Philip A. Poole-Wilson, Ryden Lars

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Aims: This study was designed to determine regional differences in patient characteristics and medication use among patients entered into an international heart failure trial. Methods and Results: Data for this analysis were derived from the Assessment of Treatment with Lisinopril and Survival Study (ATLAS), a prospective randomized comparison of high- and low- dose therapy with lisinopril in patients with New York Heart Association class II, III, or IV chronic heart failure, which enrolled 3164 patients in 291 centers in 19 countries on 3 continents. Information was collected at baseline concerning patient demographics, etiology of heart failure, accompanying conditions, prior revascularization procedures, and medication use. The primary findings were a lower incidence of ischemic cardiomyopathy in southern and western Europe, more frequent diabetes in North America, and a greater use of coronary revascularization in the United States and Canada. There was substantial variation in medication use, particularly with regard to digoxin, anticoagulants, and amiodarone. Conclusions: Although there is considerable overlap in guidelines concerning the treatment of heart failure issued by authorities in Europe and North America, there are significant regional variations in medication use. Some, but not all, of these differences can be explained by differences in patient characteristics.

Original languageEnglish (US)
Pages (from-to)3-8
Number of pages6
JournalJournal of Cardiac Failure
Volume4
Issue number1
DOIs
StatePublished - Mar 1998

Fingerprint

Heart Failure
Lisinopril
North America
Therapeutics
Amiodarone
Digoxin
Treatment Failure
Cardiomyopathies
Anticoagulants
Canada
Demography
Prospective Studies
Guidelines
Survival
Incidence

Keywords

  • Angiotensin-converting enzyme inhibitors
  • Clinical trial
  • Drug therapy
  • Heart failure
  • Practice patterns

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. / Massie, Barry M.; Cleland, John G F; Armstrong, Paul W.; Packer, Milton; Poole-Wilson, Philip A.; Lars, Ryden.

In: Journal of Cardiac Failure, Vol. 4, No. 1, 03.1998, p. 3-8.

Research output: Contribution to journalArticle

Massie, Barry M. ; Cleland, John G F ; Armstrong, Paul W. ; Packer, Milton ; Poole-Wilson, Philip A. ; Lars, Ryden. / Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. In: Journal of Cardiac Failure. 1998 ; Vol. 4, No. 1. pp. 3-8.
@article{976667ed33de4676b3c70e76a86c1c19,
title = "Regional differences in the characteristics and treatment of patients participating in an international heart failure trial",
abstract = "Aims: This study was designed to determine regional differences in patient characteristics and medication use among patients entered into an international heart failure trial. Methods and Results: Data for this analysis were derived from the Assessment of Treatment with Lisinopril and Survival Study (ATLAS), a prospective randomized comparison of high- and low- dose therapy with lisinopril in patients with New York Heart Association class II, III, or IV chronic heart failure, which enrolled 3164 patients in 291 centers in 19 countries on 3 continents. Information was collected at baseline concerning patient demographics, etiology of heart failure, accompanying conditions, prior revascularization procedures, and medication use. The primary findings were a lower incidence of ischemic cardiomyopathy in southern and western Europe, more frequent diabetes in North America, and a greater use of coronary revascularization in the United States and Canada. There was substantial variation in medication use, particularly with regard to digoxin, anticoagulants, and amiodarone. Conclusions: Although there is considerable overlap in guidelines concerning the treatment of heart failure issued by authorities in Europe and North America, there are significant regional variations in medication use. Some, but not all, of these differences can be explained by differences in patient characteristics.",
keywords = "Angiotensin-converting enzyme inhibitors, Clinical trial, Drug therapy, Heart failure, Practice patterns",
author = "Massie, {Barry M.} and Cleland, {John G F} and Armstrong, {Paul W.} and Milton Packer and Poole-Wilson, {Philip A.} and Ryden Lars",
year = "1998",
month = "3",
doi = "10.1016/S1071-9164(98)90502-4",
language = "English (US)",
volume = "4",
pages = "3--8",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "1",

}

TY - JOUR

T1 - Regional differences in the characteristics and treatment of patients participating in an international heart failure trial

AU - Massie, Barry M.

AU - Cleland, John G F

AU - Armstrong, Paul W.

AU - Packer, Milton

AU - Poole-Wilson, Philip A.

AU - Lars, Ryden

PY - 1998/3

Y1 - 1998/3

N2 - Aims: This study was designed to determine regional differences in patient characteristics and medication use among patients entered into an international heart failure trial. Methods and Results: Data for this analysis were derived from the Assessment of Treatment with Lisinopril and Survival Study (ATLAS), a prospective randomized comparison of high- and low- dose therapy with lisinopril in patients with New York Heart Association class II, III, or IV chronic heart failure, which enrolled 3164 patients in 291 centers in 19 countries on 3 continents. Information was collected at baseline concerning patient demographics, etiology of heart failure, accompanying conditions, prior revascularization procedures, and medication use. The primary findings were a lower incidence of ischemic cardiomyopathy in southern and western Europe, more frequent diabetes in North America, and a greater use of coronary revascularization in the United States and Canada. There was substantial variation in medication use, particularly with regard to digoxin, anticoagulants, and amiodarone. Conclusions: Although there is considerable overlap in guidelines concerning the treatment of heart failure issued by authorities in Europe and North America, there are significant regional variations in medication use. Some, but not all, of these differences can be explained by differences in patient characteristics.

AB - Aims: This study was designed to determine regional differences in patient characteristics and medication use among patients entered into an international heart failure trial. Methods and Results: Data for this analysis were derived from the Assessment of Treatment with Lisinopril and Survival Study (ATLAS), a prospective randomized comparison of high- and low- dose therapy with lisinopril in patients with New York Heart Association class II, III, or IV chronic heart failure, which enrolled 3164 patients in 291 centers in 19 countries on 3 continents. Information was collected at baseline concerning patient demographics, etiology of heart failure, accompanying conditions, prior revascularization procedures, and medication use. The primary findings were a lower incidence of ischemic cardiomyopathy in southern and western Europe, more frequent diabetes in North America, and a greater use of coronary revascularization in the United States and Canada. There was substantial variation in medication use, particularly with regard to digoxin, anticoagulants, and amiodarone. Conclusions: Although there is considerable overlap in guidelines concerning the treatment of heart failure issued by authorities in Europe and North America, there are significant regional variations in medication use. Some, but not all, of these differences can be explained by differences in patient characteristics.

KW - Angiotensin-converting enzyme inhibitors

KW - Clinical trial

KW - Drug therapy

KW - Heart failure

KW - Practice patterns

UR - http://www.scopus.com/inward/record.url?scp=0031747401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031747401&partnerID=8YFLogxK

U2 - 10.1016/S1071-9164(98)90502-4

DO - 10.1016/S1071-9164(98)90502-4

M3 - Article

VL - 4

SP - 3

EP - 8

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

IS - 1

ER -